Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Intellia Therapeutics ( (NTLA) ) has shared an update.
On May 28, 2025, Intellia Therapeutics provided a business update on its Phase 3 studies. The HAELO study for NTLA-2002 in hereditary angioedema and the MAGNITUDE-2 study for nex-z in ATTRv-PN are progressing well, with anticipated U.S. commercial launches in 2027 and 2029, respectively. The MAGNITUDE study for ATTR-CM is also on track, with over 200 patients dosed and expected enrollment completion by early 2027. Adverse events reported in the MAGNITUDE study have been consistent with earlier phases, with one recent case of asymptomatic liver transaminase elevations resolving without intervention.
The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics’ overall stock score reflects a mixed outlook. The company is making strong clinical progress with promising trial results, which is crucial for its long-term success. However, financial challenges, including persistent losses and declining revenues, weigh heavily on the score. Technical analysis suggests short-term consolidation, while valuation remains difficult due to negative earnings. The positive sentiment from recent corporate events and earnings calls provides a hopeful perspective for future growth.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics operates in the biotechnology industry, focusing on developing innovative therapies using CRISPR technology. The company is primarily engaged in creating treatments for genetic disorders, with a market focus on hereditary angioedema and amyloidosis.
Average Trading Volume: 3,501,917
Technical Sentiment Signal: Sell
Current Market Cap: $965.9M
Learn more about NTLA stock on TipRanks’ Stock Analysis page.